Patient-centered leukemia diagnostic and monitoring using the hemolink-MD
Ended Cooperative Agreement Awarded Last action
- Award ID
- R43CA221612
- Recipient
-
Tasso Inc. UEI JF2AG84MNZ77
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $245,436
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Funding agency
- National Institute of Biomedical Imaging and Bioenginering National Institutes of Health, Department of Health and Human Services
- Place of performance
- Seattle, WA 98119, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | -$7,500 | |
| Amendment | $7,500 | |
| Amendment | $15,000 | |
| Original award | $230,436 |
Quick answers
Who received award R43CA221612?
R43CA221612 was awarded to Tasso Inc. by National Cancer Institute (National Institutes of Health) on September 21, 2017.
How much is award R43CA221612 worth?
$245,436 has been obligated on R43CA221612.
Which agency awarded R43CA221612?
National Cancer Institute (National Institutes of Health) awarded R43CA221612, with funding from National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award